Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University explains how the impact of epigenetic therapy could lead to more randomized studies and new standard of care for patients with MDS and AML. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Impact of Epigenetic Therapy: Data Could Lead to Randomized Studies and New Standard of Care for Patients with MDS and AML
